AR084095A1 - Peptidos tomm34 y vacunas que los incluyen - Google Patents

Peptidos tomm34 y vacunas que los incluyen

Info

Publication number
AR084095A1
AR084095A1 ARP110104514A AR084095A1 AR 084095 A1 AR084095 A1 AR 084095A1 AR P110104514 A ARP110104514 A AR P110104514A AR 084095 A1 AR084095 A1 AR 084095A1
Authority
AR
Argentina
Prior art keywords
peptides
present application
peptidos
tomm34
vaccines
Prior art date
Application number
Other languages
English (en)
Inventor
Yusuke Nakamura
Takuya Tsunoda
Ryuji Osawa
Sachiko Yoshimura
Tomohisa Watanabe
Gaku Nakayama
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of AR084095A1 publication Critical patent/AR084095A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)

Abstract

La presente solicitud proporciona péptidos aislados o sus fragmentos derivados de la SEC ID Nº 42, los cuales se acoplan al antígeno HLA e inducen a los linfocitos T citotóxicos (CTL). Los péptidos pueden incluir una de las secuencias de aminoácidos mencionadas anteriormente en las cuales se ha realizado la sustitución, eliminación o adición de una, dos o varias secuencias de aminoácidos. La presente solicitud proporciona además composiciones farmacéuticas que incluyen estos péptidos. Los péptidos de la presente solicitud pueden usarse para el tratamiento del cáncer.
ARP110104514 2010-12-02 2011-12-02 Peptidos tomm34 y vacunas que los incluyen AR084095A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41918110P 2010-12-02 2010-12-02

Publications (1)

Publication Number Publication Date
AR084095A1 true AR084095A1 (es) 2013-04-17

Family

ID=46171433

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104514 AR084095A1 (es) 2010-12-02 2011-12-02 Peptidos tomm34 y vacunas que los incluyen

Country Status (22)

Country Link
US (3) US9125849B2 (es)
EP (1) EP2646546B1 (es)
JP (2) JP6064186B2 (es)
KR (1) KR102004900B1 (es)
CN (2) CN103339253B (es)
AR (1) AR084095A1 (es)
AU (1) AU2011336019B2 (es)
BR (1) BR112013013158B1 (es)
CA (1) CA2819463C (es)
CO (1) CO6862100A2 (es)
DK (1) DK2646546T3 (es)
EA (1) EA028216B1 (es)
ES (1) ES2677118T3 (es)
IL (1) IL226068B (es)
MX (1) MX344586B (es)
MY (1) MY166516A (es)
NZ (1) NZ611361A (es)
SG (2) SG190407A1 (es)
TW (1) TWI618541B (es)
UA (1) UA110119C2 (es)
WO (1) WO2012073459A1 (es)
ZA (1) ZA201303886B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2895600B1 (en) 2012-09-11 2020-02-19 OncoTherapy Science, Inc. Ube2t peptides and vaccines containing the same
JP2015228191A (ja) * 2014-06-03 2015-12-17 カシオ計算機株式会社 コンテンツ出力システム、コンテンツ出力方法、コンテンツ出力プログラム、および通信端末
CN107534710B (zh) * 2016-02-29 2019-07-23 京瓷办公信息系统株式会社 电子设备以及标记处理方法
HRP20220605T1 (hr) 2017-01-25 2022-07-08 Ose Immunotherapeutics Postupak za proizvodnju stabilne emulzije za isporuku peptida

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
JPH04504416A (ja) 1989-02-17 1992-08-06 コセルコ・ミモトープス・ピィ・ティ・ワイ．エル・ティ・ディ． ペプチドの使用方法と合成方法
CN1119459A (zh) * 1993-03-19 1996-03-27 柏伦格-英格尔海姆国际股份公司 肿瘤疫苗的制备方法
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO2001049310A1 (en) 2000-01-03 2001-07-12 Argonex Pharmaceuticals, Inc. C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040181344A1 (en) 2002-01-29 2004-09-16 Massachusetts Institute Of Technology Systems and methods for providing diagnostic services
EP2275544A3 (en) * 2002-06-06 2011-03-30 Oncotherapy Science, Inc. Genes and polypeptides relating to human colon cancers
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
EP2270042B1 (en) * 2002-09-12 2015-01-14 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
EP1581812B1 (en) 2003-01-06 2008-07-16 Wyeth Compositions and methods for diagnosing and treating colon cancers
DK1620456T3 (da) * 2003-04-18 2014-04-22 Biotech Synergy Inc Hla-a2 tumor-associerede antigen-peptider og præparater
HUE027330T2 (en) * 2005-07-27 2016-09-28 Oncotherapy Science Inc The TOM34 gene for colon cancer
DE602005016112D1 (de) * 2005-09-05 2009-10-01 Immatics Biotechnologies Gmbh Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
TWI615403B (zh) * 2007-02-21 2018-02-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201425333A (zh) * 2007-04-11 2014-07-01 Oncotherapy Science Inc 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗
ES2617434T3 (es) * 2009-03-18 2017-06-19 Oncotherapy Science, Inc. Péptidos NEIL3 y vacunas que incluyen los mismos

Also Published As

Publication number Publication date
KR20130121910A (ko) 2013-11-06
AU2011336019A1 (en) 2013-07-04
EP2646546B1 (en) 2018-05-16
SG10201509823WA (en) 2015-12-30
EA201390811A1 (ru) 2013-12-30
TW201225973A (en) 2012-07-01
CN103339253B (zh) 2015-09-09
EP2646546A1 (en) 2013-10-09
KR102004900B1 (ko) 2019-07-29
MX2013006014A (es) 2013-07-29
CO6862100A2 (es) 2014-02-10
MX344586B (es) 2016-12-20
JP2016222676A (ja) 2016-12-28
BR112013013158A2 (pt) 2017-08-01
SG190407A1 (en) 2013-06-28
JP2014506114A (ja) 2014-03-13
DK2646546T3 (en) 2018-08-06
TWI618541B (zh) 2018-03-21
ZA201303886B (en) 2014-03-26
US9125849B2 (en) 2015-09-08
NZ611361A (en) 2014-10-31
US20150374810A1 (en) 2015-12-31
US20140023671A1 (en) 2014-01-23
BR112013013158B1 (pt) 2020-04-28
EP2646546A4 (en) 2015-12-23
CA2819463C (en) 2018-10-23
CA2819463A1 (en) 2012-06-07
JP6064186B2 (ja) 2017-01-25
MY166516A (en) 2018-07-05
IL226068A0 (en) 2013-06-27
UA110119C2 (xx) 2015-11-25
AU2011336019B2 (en) 2016-07-07
IL226068B (en) 2019-01-31
ES2677118T3 (es) 2018-07-30
CN105111281A (zh) 2015-12-02
WO2012073459A1 (en) 2012-06-07
EA028216B1 (ru) 2017-10-31
US9585948B2 (en) 2017-03-07
CN103339253A (zh) 2013-10-02
US20170198010A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
CL2017001819A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer
CY1121258T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενων των ογκων των νευρωνων και του εγκεφαλου
CY1119739T1 (el) Καινοτομος ανοσοθεραπεια εναντι ογκων του εγκεφαλου
PE20191345A1 (es) Administracion viral de neoantigenos
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
CY1124950T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ
EA201071297A1 (ru) Новые и действенные пептиды мнс ii класса, полученные из сурвивина
MX2011008763A (es) Peptidos foxm1 y vacunas que contienen los mismos.
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
PE20181897A1 (es) Inmunoterapia contra el melanoma y otros tipos de cancer
AR084095A1 (es) Peptidos tomm34 y vacunas que los incluyen
MX355759B (es) Peptidos topk y vacunas que incluyen los mismos.
EP2528937A4 (en) MODIFIED MELK PEPTIDES AND ASSOCIATED VACCINES
MX2013014489A (es) Peptidos sema5b y vacunas que incluyen los mismos.
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
EP3868778A3 (en) Cdc45l peptides and vaccines including the same
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
MX2019012083A (es) Nueva vacuna de peptidos contra la pcsk9.
SG10201408245WA (en) Tmem22 peptides and vaccines including the same
BR112013009276A2 (pt) peptídeos de c18orf54 e vacinas incluindo os mesmos
MX2013004417A (es) Peptidos wdhd1 y vacunas que los incluyen.

Legal Events

Date Code Title Description
FB Suspension of granting procedure